- Home
- HUBS vs ALNY Comparison
HUBS vs ALNY Comparison
Compare HUBS & ALNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HUBS
- ALNY
- Stock Information
- Founded
- HUBS 2005
- ALNY 2002
- Country
- HUBS United States
- ALNY United States
- Employees
- HUBS N/A
- ALNY N/A
- Industry
- HUBS Computer Software: Prepackaged Software
- ALNY Biotechnology: Pharmaceutical Preparations
- Sector
- HUBS Technology
- ALNY Health Care
- Exchange
- HUBS Nasdaq
- ALNY Nasdaq
- Market Cap
- HUBS 34.3B
- ALNY 34.7B
- IPO Year
- HUBS 2014
- ALNY 2004
- Fundamental
- Price
- HUBS $720.05
- ALNY $246.80
- Analyst Decision
- HUBS Buy
- ALNY Buy
- Analyst Count
- HUBS 23
- ALNY 23
- Target Price
- HUBS $666.26
- ALNY $298.59
- AVG Volume (30 Days)
- HUBS 578.3K
- ALNY 955.4K
- Earning Date
- HUBS 11-06-2024
- ALNY 10-31-2024
- Dividend Yield
- HUBS N/A
- ALNY N/A
- EPS Growth
- HUBS N/A
- ALNY N/A
- EPS
- HUBS N/A
- ALNY N/A
- Revenue
- HUBS $2,506,280,000.00
- ALNY $2,094,795,000.00
- Revenue This Year
- HUBS $21.88
- ALNY $25.14
- Revenue Next Year
- HUBS $15.99
- ALNY $17.13
- P/E Ratio
- HUBS N/A
- ALNY N/A
- Revenue Growth
- HUBS 21.78
- ALNY 21.54
- 52 Week Low
- HUBS $434.84
- ALNY $141.98
- 52 Week High
- HUBS $728.90
- ALNY $304.39
- Technical
- Relative Strength Index (RSI)
- HUBS 78.35
- ALNY 38.74
- Support Level
- HUBS $653.53
- ALNY $229.86
- Resistance Level
- HUBS $724.61
- ALNY $271.08
- Average True Range (ATR)
- HUBS 23.05
- ALNY 9.06
- MACD
- HUBS 5.15
- ALNY -3.22
- Stochastic Oscillator
- HUBS 94.63
- ALNY 29.87
About HUBS HubSpot Inc.
HubSpot provides a cloud-based marketing, sales, and customer service software platform referred to as the growth platform. The applications are available ala carte or packaged together. HubSpot's mission is to help companies grow better and has expanded from its initial focus on inbound marketing to embrace marketing, sales, and service more broadly. The company was founded in 2006, completed its initial public offering in 2014, and is headquartered in Cambridge, Massachusetts.
About ALNY Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.